Industry
Biotechnology
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
April 22, 2024 | 1:41 pm
Portfolio Pulse from Benzinga Insights
April 22, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 9:05 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 8:55 pm
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Insights
February 19, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
February 16, 2024 | 1:10 pm
Portfolio Pulse from Benzinga Insights
February 16, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
February 15, 2024 | 5:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.